{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:30:46Z","timestamp":1740162646380,"version":"3.37.3"},"reference-count":34,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,6,24]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>In Australia, therapeutic interchange of angiotensin-converting enzyme (ACE) inhibitors could generate savings for patients and the Pharmaceutical Benefits Scheme (PBS). The PBS subsidises nine drugs in the ACE inhibitor class. These drugs are therapeutically equivalent, but the price varies between each drug. Patients are key players in successful therapeutic interchange programmes, but little is known about their views. This study aims to explore patient views of therapeutic interchange of ACE inhibitors in Australian primary care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Qualitative exploratory research study using semi-structured interviews, asking participants about therapeutic interchange and their attitude towards hypothetically switching ACE inhibitors. Data were analysed thematically.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Australian primary care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Fourteen adults in Australia currently taking an ACE inhibitor, recruited via general practices and pharmacies, social media and professional networks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>Five key themes were identified: participants\u2019 limited understanding of medication; the expectation that a new drug would be \u2018the same\u2019; the view that choice, convenience and fear of change outweigh the cost; altruism; and trust in health professionals, particularly participants\u2019 own general practitioner (GP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients\u2019 limited understanding of medication changes poses a barrier to therapeutic interchange. Clinicians should explore patients\u2019 understanding and expectations of therapeutic interchange. Counselling from trusted health professionals, particularly GPs, could ameliorate concerns. Policymakers implementing therapeutic interchange programmes should ensure a trusted GP directs medication changes.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2020-044806","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T16:38:49Z","timestamp":1626107929000},"page":"e044806","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Patient views of therapeutic interchange of ACE inhibitors in Australian primary care: a qualitative study"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-1172","authenticated-orcid":false,"given":"Tessa","family":"Marshall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hok","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyllis","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"2024102810415290000_11.7.e044806.1","unstructured":"ACE inhibitors . ACE inhibitors - Australian medicines handbook, 2019. Available: https:\/\/amhonline-amh-net-au.ezp.lib.unimelb.edu.au\/chapters\/cardiovascular-drugs\/antihypertensives\/ace-inhibitors"},{"key":"2024102810415290000_11.7.e044806.2","unstructured":"Blood Pressure Reduction | Therapeutic Guidelines . Angiotensin convert. enzyme Inhib. Reduce blood press, 2019. Available: https:\/\/tgldcdp-tg-org-au.ezp.lib.unimelb.edu.au\/viewTopic?topicfile=blood-pressure-reduction&guidelineName=Cardiovascular#toc_d1e249"},{"key":"2024102810415290000_11.7.e044806.3","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12237"},{"key":"2024102810415290000_11.7.e044806.4","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002554","article-title":"Comparison of the efficacy and safety of different ACE inhibitors in patients with chronic heart failure","volume":"95","author":"Sun","year":"2016","journal-title":"Medicine"},{"key":"2024102810415290000_11.7.e044806.5","unstructured":"FDA . Research C for DE and. Drugs@FDA Glossary of Terms, 2018. Available: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drugsfda-glossary-terms"},{"key":"2024102810415290000_11.7.e044806.6","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31822d97d5"},{"key":"2024102810415290000_11.7.e044806.7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00228-018-2573-7","article-title":"Systematic literature review of the methodology for developing pharmacotherapeutic interchange guidelines and their implementation in hospitals and ambulatory care settings","volume":"75","author":"Adrover-Rigo","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"2024102810415290000_11.7.e044806.8","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.18553\/jmcp.2018.24.12.1260","article-title":"State approaches to therapeutic interchange in community pharmacy settings: legislative and regulatory authority","volume":"24","author":"Vanderholm","year":"2018","journal-title":"JMCP"},{"key":"2024102810415290000_11.7.e044806.9","unstructured":"Canadian Pharmacists Association . Pharmacists\u2019 scope of practice in Canada, 2020. Available: https:\/\/www.pharmacists.ca\/cpha-ca\/assets\/File\/cpha-on-the-issues\/Scope%20of%20Practice%20in%20Canada_Jan2020.pdf"},{"key":"2024102810415290000_11.7.e044806.10","unstructured":"HSE.ie . Preferred drugs, 2020. Available: https:\/\/www.hse.ie\/eng\/about\/who\/cspd\/ncps\/medicines-management\/preferred-drugs\/preferred-drugs.html"},{"key":"2024102810415290000_11.7.e044806.11","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1742-1241.2010.02423.x","article-title":"Clinical and economic outcomes in patients switched to simvastatin in a community-based family medicine practice: clinical and economic outcomes in patients switched to simvastatin","volume":"64","author":"Willey","year":"2010","journal-title":"Int J Clin Pract"},{"key":"2024102810415290000_11.7.e044806.12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.clpt.2005.12.304","article-title":"A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences","volume":"79","author":"Schneeweiss","year":"2006","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"2024102810415290000_11.7.e044806.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7554.1344"},{"key":"2024102810415290000_11.7.e044806.14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1071\/AH17177","article-title":"Therapeutic equivalence program: continued economic benefits in the context of rising costs and increased demand","volume":"43","author":"Chynoweth","year":"2018","journal-title":"Aust Health Rev Publ Aust Hosp Assoc"},{"key":"2024102810415290000_11.7.e044806.15","unstructured":"Australian Government Department of Health . Schedule of pharmaceutical benefits (Volume 1 - general schedule), 2020. Available: https:\/\/www.pbs.gov.au\/publication\/schedule\/2020\/02\/2020-02-01-general-schedule-volume-1.pdf"},{"key":"2024102810415290000_11.7.e044806.16","unstructured":"Medicare Australia . Medicare Australia - statistics - pharmaceutical benefits schedule item statistics, 2020. Available: http:\/\/medicarestatistics.humanservices.gov.au\/statistics\/pbs_item.jsp"},{"key":"2024102810415290000_11.7.e044806.17","unstructured":"Schedule Online . Pharmaceutical benefits schedule item reports, 2019. Available: https:\/\/www.pharmac.govt.nz\/wwwtrs\/ScheduleOnline.php?code=A070701"},{"key":"2024102810415290000_11.7.e044806.18","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/clc.22975","article-title":"Understanding patient adherence and concerns with statins and medication discussions with physicians (action): a survey on the patient perspective of dialogue with healthcare providers regarding statin therapy","volume":"41","author":"Brinton","year":"2018","journal-title":"Clin Cardiol"},{"key":"2024102810415290000_11.7.e044806.19","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s11096-016-0370-x","article-title":"Patients' knowledge and attitude towards therapeutic reference pricing system in Slovenia","volume":"38","author":"Mar\u0111etko","year":"2016","journal-title":"Int J Clin Pharm"},{"key":"2024102810415290000_11.7.e044806.20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2125.2012.04183.x","article-title":"Implementing a statin switching programme in primary care: patients\u2019 views and experiences","volume":"74","author":"Krska","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2024102810415290000_11.7.e044806.21","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.7.500.33677"},{"key":"2024102810415290000_11.7.e044806.22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11845-016-1535-2","article-title":"Patient acceptability and experiences of therapeutic switching of proton pump inhibitors within the National preferred drugs initiative in Ireland","volume":"186","author":"O\u2019Connor","year":"2017","journal-title":"Ir J Med Sci"},{"key":"2024102810415290000_11.7.e044806.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2006.01217.x"},{"key":"2024102810415290000_11.7.e044806.24","first-page":"631","article-title":"Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy","volume":"5","author":"Condra","year":"1999","journal-title":"Am J Manag Care"},{"key":"2024102810415290000_11.7.e044806.25","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.16.2491"},{"key":"2024102810415290000_11.7.e044806.26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.5694\/j.1326-5377.2011.tb03145.x","article-title":"A therapeutic equivalence program: evidence\u2010based promotion of more efficient use of medicines","volume":"194","author":"Larmour","year":"2011","journal-title":"Medical Journal of Australia"},{"key":"2024102810415290000_11.7.e044806.27","doi-asserted-by":"crossref","unstructured":"Moustakas C . Phenomenological research methods. Thousand Oaks: SAGE Publications Ltd, 1994.","DOI":"10.4135\/9781412995658"},{"key":"2024102810415290000_11.7.e044806.28","unstructured":"QSR International Pty Ltd . NVivo qualitative data analysis software, version 12. Doncaster Victoria, Australia: QSR International Pty Ltd, 2018."},{"key":"2024102810415290000_11.7.e044806.29","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"2024102810415290000_11.7.e044806.30","unstructured":"Health AGD of Pharmaceutical Benefits Scheme (PBS) . About the PBS, 2020. Available: http:\/\/www.pbs.gov.au\/info\/about-the-pbs"},{"key":"2024102810415290000_11.7.e044806.31","unstructured":"Global Healthy Living Foundation . Tennessee patient Sentiment toward non-medical drug switching, 2016. Available: https:\/\/creakyjoints.org\/advocacy\/tennessee-patient-sentiment-toward-non-medical-drug-switching\/"},{"key":"2024102810415290000_11.7.e044806.32","unstructured":"Global Healthy Living Foundation . Florida patient Sentiment toward non-medical drug switching \u2013 CreakyJoints, 2016. Available: https:\/\/creakyjoints.org\/advocacy\/florida-patient-sentiment-toward-non-medical-drug-switching\/"},{"key":"2024102810415290000_11.7.e044806.33","unstructured":"Global Healthy Living Foundation . Massachusetts patient Sentiment toward non-medical drug switching, 2017. Available: https:\/\/creakyjoints.org\/advocacy\/massachusetts-patient-sentiment-toward-non-medical-drug-switching\/"},{"key":"2024102810415290000_11.7.e044806.34","unstructured":"Global Healthy Living Foundation . New York patient Sentiment toward non-medical drug switching, 2018. Available: https:\/\/creakyjoints.org\/advocacy\/new-york-patient-sentiment-toward-non-medical-drug-switching\/"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-044806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T17:48:20Z","timestamp":1730137700000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-044806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,12]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/bmjopen-2020-044806"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-044806","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}